We’ve joined the NIH Office of the Director and several institutes in two Rapid Acceleration of Diagnostics Radical (RADx-rad) initiative funding opportunity announcements (FOAs). These FOAs offer an excellent opportunity for NIGMS-supported researchers with expertise in technology development and/or artificial intelligence/machine learning to conduct innovative research addressing the public health emergency caused by COVID-19.Continue reading “Funding Opportunities: Rapid Acceleration of Diagnostics Radical (RADx-rad) Emergency Awards”
We’re pleased to announce our participation in Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP), a $500 million NIH-wide initiative to reduce morbidity and mortality disparities for vulnerable and underserved populations disproportionately affected by COVID-19. The initiative will fund a national coordination center and a group of interlinked projects across the United States aimed at improving COVID-19 testing and understanding COVID-19 health disparities.
The announcements for RADx-UP are:Continue reading “Funding Opportunities: Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP)”
Because many people in the research community are facing considerable challenges trying to juggle various responsibilities during the COVID-19 outbreak, NIGMS will accommodate late application submissions for due dates in May 2020 for all NIGMS-specific FOAs (see NOT-GM-20-029). For applications submitted through June 30, 2020, institutions do not need to request advance permission or provide a cover letter to justify a late submission to these FOAs. Applications with due dates prior to May 25 should use FORMS E and those with due dates on or after May 25 should use FORMS F, regardless of the date of submission.Continue reading “Policy on Late Submissions of NIGMS Applications Due in May 2020”
We’ve published a notice of special interest (NOSI) (NOT-GM-20-025) to address the urgent need for research on the SARS-CoV-2 virus. We’ll accept competitive revisions (supplements) in three specific scientific areas:
- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all grant and cooperative agreement activity codes)
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only)
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only)